By admin 
The Cancer Research Institute (CRI), a global leader in advancing immunotherapy, is highlighting the profound impact of legacy gifts through wills and trusts, particularly as August is designated Make-A-Will Month. This period serves as a crucial reminder for individuals to consider how their estate planning can contribute to life-saving scientific research, helping to propel the mission of creating a world free from the devastation of cancer. Such planned giving represents a deeply personal and enduring commitment, ensuring that the fight against cancer continues with robust funding for the brightest minds in immunotherapy.
The Urgent Imperative of Cancer Research
Cancer remains a formidable global health challenge, affecting millions of lives annually. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The sheer scale of this public health crisis underscores the continuous and urgent need for innovative research and development into more effective treatments and, ultimately, cures. For decades, traditional cancer therapies such as surgery, chemotherapy, and radiation have been the mainstays of treatment, offering significant benefits but often accompanied by severe side effects and limitations in efficacy for advanced or aggressive cancers. The quest for more targeted, less toxic, and highly effective treatments has driven scientific inquiry for generations.
Immunotherapy: A Paradigm Shift in Cancer Treatment
In recent decades, the field of oncology has witnessed a revolutionary transformation with the advent and rapid advancement of immunotherapy. Unlike conventional treatments that directly attack cancer cells or tumors, immunotherapy harnesses the body’s own immune system to recognize and destroy malignant cells. This approach represents a fundamental paradigm shift, offering new hope for patients who previously had limited options. The journey to unlock the power of the immune system against cancer has been long and arduous, marked by decades of fundamental research into immunology, cell biology, and oncology. Early pioneers faced skepticism and numerous setbacks, but their persistence laid the groundwork for the breakthroughs we see today.
The development of checkpoint inhibitors, which block proteins that prevent immune cells from attacking cancer, and CAR T-cell therapy, which involves genetically modifying a patient’s own T cells to target cancer, are just two examples of how immunotherapy has reshaped cancer care. These therapies have demonstrated remarkable success in treating various cancers, including melanoma, lung cancer, lymphoma, and leukemia, often leading to durable remissions and improved survival rates for patients with advanced disease. However, immunotherapy is not a universal cure; many patients still do not respond, or they develop resistance, highlighting the ongoing need for deeper understanding and further innovation.
The Cancer Research Institute: A Legacy of Pioneering Support
The Cancer Research Institute (CRI) has been at the forefront of this immunological revolution for over 70 years. Founded in 1953, CRI was established with the visionary understanding that the immune system held the key to conquering cancer. At a time when the concept of immunotherapy was largely dismissed by the broader scientific community, CRI steadfastly committed itself to funding basic and translational research focused on the immune system’s role in cancer. This unwavering dedication positioned CRI as a true pioneer, providing critical early-stage funding to scientists exploring radical new ideas that would eventually blossom into today’s life-saving treatments.
Throughout its history, CRI has played a pivotal role in nurturing the field of cancer immunology. From supporting foundational discoveries about how immune cells function and interact with cancer to funding the clinical trials that brought breakthrough therapies to patients, CRI’s influence is undeniable. Its commitment to fostering a collaborative global network of researchers has accelerated progress, ensuring that knowledge is shared and built upon efficiently. This chronological journey from a niche scientific interest to a mainstream, highly effective treatment modality owes much to the sustained support and strategic vision of organizations like CRI.
The Enduring Power of Legacy Gifts
For many, the decision to include CRI in their will or living trust is a deeply personal act, rooted in a desire to contribute to a cause that has directly impacted their lives or the lives of their loved ones. Supporters often cite their profound appreciation for the life-saving immunotherapy treatments they or their family members have received, viewing a legacy gift as a way to "pay it forward" and ensure that future generations benefit from similar advancements. Others are driven by a more general gratitude that CRI has consistently pushed the boundaries of scientific understanding, acting as a relentless force for progress in a complex and challenging field. All who choose to make such a gift share a fundamental understanding of the critical importance of CRI’s work and its potential to alleviate suffering on a global scale.
Legacy gifts, often referred to as planned giving, offer a simple yet incredibly flexible way for individuals to make a significant charitable contribution without impacting their current financial security. These gifts typically take effect after a donor’s lifetime, allowing them to provide for their loved ones first while still leaving a lasting philanthropic mark. This method of giving ensures sustainable funding for long-term research initiatives, which are essential for tackling complex diseases like cancer. Scientific breakthroughs often require years, if not decades, of sustained investment, and legacy gifts provide the bedrock for such enduring commitments.
Financial Stewardship and Public Trust: A Foundation of Confidence
Donors considering a legacy gift to the Cancer Research Institute can do so with utmost confidence, knowing that the organization operates with exemplary governance and fiscal responsibility. As Katherine Pooser, Director of Planned Giving, emphasized, "When a person generously gives through a will or living trust, they can do so with confidence knowing CRI regularly receives recognition from third-party assessors for its good governance and fiscal responsibility." This external validation is crucial for demonstrating transparency and accountability, ensuring that donor funds are utilized efficiently and effectively to maximize their impact on research.
CRI consistently earns high ratings from independent charity evaluators, such as a 4-star rating from Charity Navigator – its highest possible distinction – and a Platinum Seal of Transparency from GuideStar. These accolades are not merely symbolic; they reflect a rigorous adherence to best practices in financial management, organizational effectiveness, and ethical fundraising. Such ratings assure donors that CRI maintains strong financial health, allocates a significant portion of its budget directly to programs, and operates with a clear commitment to its mission. Pooser further highlighted the tangible impact of these contributions: "Supporters can also be confident that their gift makes a real difference. Bequests of every size come together to make up a substantial part of the funding that drives the next wave of immunotherapy developments." This collective power of individual gifts, regardless of their magnitude, forms a critical financial backbone for continuous innovation.
Empowering Scientists: The Engine of Progress
The generous bequests facilitated through legacy giving directly empower CRI-funded scientists to pursue rigorous, cutting-edge immunotherapy research. These investigators, working in leading institutions worldwide, are engaged in diverse projects aimed at unraveling the complexities of cancer and the immune system. Their work ranges from fundamental discoveries in immunology to the development of novel therapeutic strategies. For instance, some CRI-funded scientists are exploring the intricate connections between sensory neurons and lung cancer, seeking to understand how the nervous system might influence tumor growth and immune responses. Others are leveraging the power of artificial intelligence (AI) to analyze vast datasets of T cells, aiming to identify new biomarkers or therapeutic targets that could personalize cancer treatment.
The support provided by CRI extends beyond mere financial grants. As CRI Thompson Family Foundation CLIP Investigator Lloyd Bod, PhD, an assistant professor of medicine at Massachusetts General Hospital, articulated, "Being a CRI CLIP Investigator is an honor, and not only provides crucial funding, but also also connects me with a network of researchers dedicated to making groundbreaking discoveries in immunotherapy." This comprehensive support system, encompassing funding, mentorship, and a collaborative network, fosters an environment where bold ideas can flourish. Dr. Bod further emphasized, "It is a commitment to pursuing innovative science that can lead to life-saving therapies for patients worldwide." This sentiment is echoed by countless other researchers who benefit from CRI’s commitment to immunotherapy, understanding that their work, made possible by community support, holds the key to future medical breakthroughs.
Indeed, the impact of this funding can be felt not just in research labs but in patient clinics. Consider the story of Sarah, a hypothetical patient diagnosed with advanced melanoma. Years ago, her prognosis would have been grim. Thanks to the relentless work of scientists supported by organizations like CRI, immunotherapy became a viable option. Sarah’s oncologist prescribed a checkpoint inhibitor, a treatment developed from basic research into T-cell function. After several months, Sarah’s tumors had significantly shrunk, and she experienced a durable remission, allowing her to return to a full and active life. While Sarah may not know the names of the donors who made her treatment possible, their legacy gifts created the scientific ecosystem necessary for such a profound outcome. "I am incredibly grateful for the research that saved my life," Sarah might say, reflecting the sentiment of countless beneficiaries. "Knowing that people chose to support this vital work through their wills gives me hope for everyone else fighting this disease."
Broader Impact and Future Implications: A World Immune to Cancer
The collective impact of legacy gifts extends far beyond individual research projects; it contributes significantly to the long-term vision of creating a world immune to cancer. This ambitious goal encompasses not only developing cures for existing cancers but also understanding mechanisms of prevention, early detection, and ultimately, prophylactic strategies that could protect individuals from ever developing the disease. Continuous investment in basic science is paramount, as today’s fundamental discoveries often become tomorrow’s clinical treatments. Legacy gifts provide the stable, unrestricted funding necessary for scientists to pursue high-risk, high-reward research that might not fit conventional funding models but holds immense potential for transformative breakthroughs.
As immunotherapy continues to evolve, the need for sustained philanthropic support will only grow. Future research aims to address current challenges, such as identifying biomarkers to predict treatment response, overcoming resistance mechanisms, developing personalized immunotherapies, and exploring combination strategies to improve efficacy across a broader spectrum of cancers. The implications of achieving a world immune to cancer are profound, promising not only a reduction in human suffering and mortality but also significant economic benefits by reducing healthcare burdens and increasing productivity.
By choosing to include CRI in their will or living trust, donors become an integral part of this inspiring journey. They are not merely making a donation; they are investing in the future of medicine, in the brilliance of scientific inquiry, and in the enduring hope for a healthier world. Regardless of the specific details of a will, CRI expresses profound gratitude for every contribution, recognizing that each gift fuels the relentless pursuit of scientific research conducted by the brightest minds in immunotherapy.
For individuals who are considering how to leave a lasting impact through their estate, August’s Make-A-Will Month presents an opportune moment for reflection and action. The process of establishing a will or living trust is a straightforward yet powerful way to ensure one’s final wishes are honored and that their values continue to shape the world. For those with questions about wills, bequests, or other planned giving options, the Cancer Research Institute’s office of gift planning is available to provide guidance and support at 212-792-5212, ensuring that every donor can confidently make a gift that helps create a world immune to cancer.
